Literature DB >> 8897868

Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide.

K E Fattinger1, D Verotta, H C Porchet, A Munafo, J Y Le Cotonnec, L B Sheiner.   

Abstract

A pharmacodynamic analysis of the input-response relationship between the gonadotropin-releasing hormone antagonist antide and luteinizing hormone (LH) and testosterone concentrations is presented. A control compartmental model is developed using pharmacokinetic and pharmacodynamic data from experiments in which different short intravenous antide infusions were given to healthy male volunteers. Because of the control interdependence between serum LH and testosterone a separation principle similar to one we have used previously to analyze physiological pharmacokinetic data is used for model exploration: testosterone and LH are first modeled separately, conditioning on the other observed response. This reveals that the LH effect on testosterone depends on previous LH exposure and that LH depends not on current but on previous testosterone exposure, resulting in an LH overshoot after antide-induced suppression. Both submodels are combined into one global model, which in addition includes a model for testosterone circadian variation. This model describes the data well and can be used to predict responses for some nonstudied antide dosages. However, the sensitivity of predictions to model assumptions limits the range of valid extrapolation, and this, too, is illustrated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897868     DOI: 10.1152/ajpendo.1996.271.4.E775

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 2.  Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics.

Authors:  A Dokoumetzidis; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

3.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

4.  Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheinerz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

5.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

6.  Volterra series in pharmacokinetics and pharmacodynamics.

Authors:  Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

Review 7.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

Review 8.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

9.  A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.

Authors:  Chay Ngee Lim; Ahmed Hamed Salem
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

10.  Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs.

Authors:  M Schwahn; N V Nagaraja; H Derendorf
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.